Cost-effectiveness simulation model of abatacept versus anti-TNF treatment strategies in rheumatoid arthritis in France

被引：0
|
作者：
Saraux, Alain [1 ]
Goupille, Philippe [2 ]
Gossec, Laure [3 ]
Bregman, Bruno [4 ]
Boccard, Eric [4 ]
Dupont, Danielle [5 ]
Beresmak, Ariel [6 ,7 ]
机构：
[1] Hop Cavale Blanche, Brest, France
[2] Univ Tours, CHRU Tours, Serv Rhumatol, Tours, France
[3] Cochin Hosp, Rheumatol B Dept, Paris, France
[4] Bristol Myers Squibb Co, Rueil Malmaison, France
[5] Bristol Myers Squibb Co, Int Corp, Braine Lalleud, Belgium
[6] Univ Paris 05, LIRAES, Paris, France
[7] Data Mining Int, Geneva, Switzerland
来源：
ARTHRITIS AND RHEUMATISM | 2008年 / 58卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
797
引用
收藏
页码：S463 / S463
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE
    Gossec, L.
    Goupille, P.
    Saraux, A.
    Bregman, B.
    Boccard, E.
    Dupont, D.
    Beresniak, A.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A542 - A543
  • [2] Cost-effectiveness of abatacept versus other biologic agents in dmards and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis in Canada
    Haraoui, B.
    Russell, A.
    Thorne, C.
    [J]. JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1628 - 1628
  • [3] Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis
    Anthony Russell
    Ariel Beresniak
    Louis Bessette
    Boulos Haraoui
    Proton Rahman
    Carter Thorne
    Ross Maclean
    Danielle Dupont
    [J]. Clinical Rheumatology, 2009, 28
  • [4] Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis
    Russell, Anthony
    Beresniak, Ariel
    Bessette, Louis
    Haraoui, Boulos
    Rahman, Proton
    Thorne, Carter
    Maclean, Ross
    Dupont, Danielle
    [J]. CLINICAL RHEUMATOLOGY, 2009, 28 (04) : 403 - 412
  • [5] Comparative Effectiveness of Abatacept Versus Subsequent Anti-TNF Agents Among Rheumatoid Arthritis Patients with Previous Anti-TNF Exposure.
    Harrold, Leslie R.
    Reed, George
    Curtis, Jeffrey R.
    Solomon, Daniel H.
    Hochberg, Marc
    Onofrei, Alina U.
    Kremer, Joel M.
    Greenberg, Jeffrey D.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1019 - S1019
  • [6] A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY
    Brodszky, V
    Borgstrom, F.
    Arnetorp, S.
    Pentek, M.
    Gulacsi, L.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A549 - A550
  • [7] COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA) PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TNF TREATMENT IN TURKEY
    Ertenli, I
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A445 - A445
  • [8] ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A223 - A224
  • [9] COST-EFFECTIVENESS OF ABATACEPT OR INFLIXIMAB IN RHEUMATOID ARTHRITIS IN COLOMBIA
    Alfonso-Cristancho, R.
    Aiello, E. C.
    Roa, C. N.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A127 - A127
  • [10] Anti-TNF Treatment in Rheumatoid Arthritis
    Geiler, Janina
    Buch, Maya
    McDermott, Michael F.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (29) : 3141 - 3154
12345